AKTX - MCAP CO - Akari Therapeutics

Protein-based drug logistics at Akari Therapeutics (AKTX) rely on strict control of international cold chains. The operating model is based on outsourcing production and testing, which minimizes capital expenditures. This chart of share price quotes shows a market capitalization of 0.02. Business development is pursued through mergers with biotech firms to create synergy in the therapy of complex blood diseases.

Market capitalization reflects the aggregate value of all shares, defining the scale of the business in the eyes of the market. Professionals utilize this parameter to assess whether an asset is overbought or to identify entry points. By analyzing the market capitalization history of a company, an investor identifies critical capital support levels. For Akari Therapeutics (AKTX), this indicator correlates with the value of the Nomacopan patents. The business value here directly depends on the monopoly control over rare disease therapy.